Frontiers in Bioengineering and Biotechnology · 2022 · 15 citations · 43 references
MedicineEndocrinologyPharmacologyAgingPain MedicineReproductive EndocrinologyAge-related Musculoskeletal ChangesHormonal TherapyMenopause Hormone TherapyMenopause PharmacotherapyOsteoporosis PharmacotherapySteroid Hormone SignalingEstrogen PharmacologyEstrogen Receptor SignalingEstrogen ReceptorsEstrogen Signaling DisruptionIntervertebral Disc DegenerationPostmenopausal Osteoporosis Treatment
Estrogen agonist raloxifene is an FDA-approved treatment of osteoporosis in postmenopausal women, which may also be a promising prophylactic for painful intervertebral disc (IVD) degeneration. Here, we hypothesized that 1) aging and biological sex contribute to IVD degeneration by reducing estrogen signaling and that 2) raloxifene stimulates estrogen signaling to protect against age- and sex-related IVD degeneration in mice. 2.5-month-old (male and female) and 22.5-month-old (female) C57Bl/6J mice were subcutaneously injected with raloxifene hydrochloride 5x/week for 6 weeks ( n = 7–9/grp). Next, female mice were ovariectomized (OVX) or sham operated at 4 months of age and tissues harvested at 6 months ( n = 5–6/grp). Advanced aging and OVX increased IVD degeneration score, weakened IVD strength, reduced estrogen receptor-α (ER-α) protein expression, and increased neurotransmitter substance P (SP) expression. Similar to aging and compared with male IVDs, female IVDs were more degenerated, mechanically less viscoelastic, and expressed less ER-α protein, but unlike the effect induced by aging or OVX, IVD mechanical force was greater in females than in males. Therapeutically, systemic injection of raloxifene promoted ER-α protein to quell these dysregulations by enlarging IVD height, alleviating IVD degeneration score, increasing the strength and viscoelastic properties of the IVD, and reducing IVD cell expression of SP in young-adult and old female mice. Transcriptionally, injection of raloxifene upregulated the gene expression of ER-α and extracellular matrix-related anabolism in young-adult and old IVD. In vertebra, advanced aging and OVX reduced trabecular BV/TV, whereas injection of raloxifene increased trabecular BV/TV in young-adult and old female mice, but not in young-adult male mice. In vertebra, advanced aging, OVX, and biological sex (females > males) increased the number of SP-expressing osteocytes, whereas injection of raloxifene reduced the number of SP-expressing osteocytes in young-adult female and male mice and old female mice. Overall, injection of estrogen agonist raloxifene in mice normalized dysregulation of IVD structure, IVD mechanics, and pain-related SP expression in IVD cells and osteocytes induced by aging and biological sex. These data suggest that, in addition to bone loss, raloxifene may relieve painful IVD degeneration in postmenopausal women induced by advanced age, biological sex, and estrogen depletion.
43
Nerve ingrowth into diseased intervertebral disc in chronic back pain
TE Peacock, Philippe Goupille, JA Hoyland et al. · The Lancet · 1997 · 978 citations
The Association Between Lumbar Disc Degeneration and Low Back Pain
Evelien de Schepper, Jurgen Damen, Joyce B. J. van Meurs et al. · Spine · 2010 · 459 citations
Junqing Wang, Jùn-Qīng Wáng, Zoltán Káplár · Quantitative Imaging in Medicine and Surgery · 2016 · 298 citations · Full text
Wnt/β-Catenin and Estrogen Signaling Converge in Vivo
Alexander Kouzmenko, Ken‐ichi Takeyama, Saya Ito et al. · Journal of Biological Chemistry · 2004 · 219 citations · Full text